Overcoming the challenges of off-the-shelf allogeneic cell therapies
Chimeric antigen receptor T-cell therapy has emerged as one of the major breakthroughs in cancer immunotherapy in the last decade. In a video interview at the 2022 Biotechnology Innovation Organization International Convention in San Diego, Dr. Jason Litten discussed the challenges that need to be overcome for allogeneic T cells to reach clinical success. Read More
Struggle to include women in clinical trials continues despite gains
Though female participation in clinical trials has been steadily improving over the years, most of the women enrolled in trials are white and not members of minority groups. ScienceBoard.net spoke with Kathryn Schubert, president and CEO of the Society for Women's Health Research, about inclusivity in clinical trials at the 2022 Biotechnology Innovation Organization International Convention in San Diego. Read More
Patient advocacy organizations look to partner with pharma companies
Patient advocacy organizations are looking to partner with pharmaceutical companies, offering resources and expertise to maximize the impact and efficiency of their therapeutic R&D programs. It’s a message that these groups want to drive home to pharma at the 2022 Biotechnology Innovation Organization International Convention in San Diego. Read More
How to develop a sustainable portfolio for cell, gene therapy platforms
Michael Retterath, a Biotechnology Innovation Organization International Convention 2022 panelist and chief business officer at Spark Therapeutics, spoke to ScienceBoard.net about his company’s transition from a research center to a private, venture-backed startup and a publicly traded company. Read More
Biotech industry execs, not scientists, remain male-dominated
A panel at the 2022 Biotechnology Innovation Organization International Convention will explore how to close the gender gap in the biotech industry and how it can become more inclusive. ScienceBoard.net spoke with Nasha Fitter, co-founder and CEO of the FOXG1 Research Foundation, who will participate in the June 14 panel at the convention. Read More
Taking cell therapy to the next level with 3D bioprinting of human tissues
Aspect Biosystems is working to create breakthrough tissue therapeutics that have the potential to profoundly impact patients with 3D bioprinting of human tissues, contends Eric Roos, chief business development officer. Roos spoke with ScienceBoard.net at the American Society of Gene & Cell Therapy 2022 annual meeting in Washington, DC. Read More
Overcoming the blood-brain barrier for gene therapy delivery with AAV capsids
Current gene delivery to the central nervous system continues to be a challenge, according to Amy Pooler, PhD, vice president of neuroscience at Sangamo Therapeutics. Pooler spoke with ScienceBoard.net at the American Society of Gene & Cell Therapy 2022 annual meeting about how Sangamo’s adeno-associated virus (AAV) capsids are designed to overcome the blood-brain barrier. Read More
Decibel Therapeutics develops treatments to restore and improve hearing, balance
Decibel Therapeutics is helping to break down the barriers to understanding the molecular pathways and cell physiology inside the inner ear by integrating single-cell genomics, bioinformatic analyses, and precision gene therapy technologies, contends CEO Laurence Reid, PhD. Reid spoke with ScienceBoard.net at the American Society of Gene & Cell Therapy 2022 annual meeting in Washington, DC. Read More
Mustang Bio focuses on CD20 antigen for CAR T-cell therapy
Biopharmaceutical company Mustang Bio is focused on a CD20-targeted autologous chimeric antigen receptor (CAR) T-cell therapy for non-Hodgkin lymphoma, chronic lymphocytic leukemia, and Waldenstrom macroglobulinemia. Dr. Bruce Dezube, senior vice president at Mustang Bio, spoke to ScienceBoard.net at the American Society of Gene & Cell Therapy 2022 annual meeting about the targeting of the CD20 antigen. Read More
Graphite Bio sees its gene editing tech as step above CRISPR
While the use of CRISPR is an effective gene editing tool on its own, Dr. Josh Lehrer, CEO of Graphite Bio, contends that the technology doesn’t correct the underlying genetic defect. CRISPR is the “cut” function and Graphite Bio’s technology is the “cut and paste” capability, Lehrer told ScienceBoard.net at the American Society of Gene & Cell Therapy 2022 annual meeting in Washington, DC. Read More
Conferences
Science Briefs
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Connect
